XTL Biopharmaceuticals Ltd.
XTLB
Rank in Stocks
#30954
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing... XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity rebranded as XTL Biopharmaceuticals Ltd. in July 1995 and is currently headquartered in Ramat Gan, Israel.
Share Price
$0.0041155
Last synced: 2026-11-09
Market Cap
$4.05M
Change (1 day)
-6.35%
Change (1 year)
-61.01%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade XTL Biopharmaceuticals Ltd. (XTLB)
Category
Healthcare
Operating Margin for XTL Biopharmaceuticals Ltd. (XTLB)
Operating Margin as of November 2026 TTM: 0.00%
According to XTL Biopharmaceuticals Ltd.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for XTL Biopharmaceuticals Ltd. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -481.60% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -122.16% | -51.36% |
| 2012 | -251.17% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | -100.00% |
| 2008 | -161.46% | -94.31% |
| 2007 | -2,837.38% | -19.72% |
| 2006 | -3,534.36% | 685.76% |
| 2005 | -449.80% | -7.39% |
| 2004 | -485.70% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about XTL Biopharmaceuticals Ltd.'s operating margin
What was XTL Biopharmaceuticals Ltd.'s operating margin in 2025?
In 2025, XTL Biopharmaceuticals Ltd.'s operating margin was 0.00%, compared with -481.60% in 2024.
How has XTL Biopharmaceuticals Ltd.'s operating margin changed since 2020?
From 2020 to 2025, XTL Biopharmaceuticals Ltd.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-481.60%).
How does XTL Biopharmaceuticals Ltd.'s operating margin compare with similar companies?
XTL Biopharmaceuticals Ltd.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.